United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bank of America

New Pacific Metals Corp

Safe-T Group Ltd - ADR

12.05 pm: S&P 500 hits a record as run of strong corporate earnings continues US stocks were higher in noon trading, boosted by corporate earnings ahead of the Federal Reserve's policy decision tomorrow afternoon. At midday, the Dow rose 91 points to 36,005, while the S&P 500 added 13 points at 4,627 and the tech-heavy Nasdaq gained 27 points to 15,623.

US stocks higher midday as Federal Reserve meets

The question now is: when will the Fed start tapering, and by how much?

Fed Meets, Tapering in Our Midst; Pfizer Beats in Q3

Amgen

Big Decisions from Outside the Market May Significantly Affect the Market

Pfizer And Amgen Release Earnings Today

Pfizer Inc (NYSE: PFE) is trading higher Tuesday after the company announced better-than-expected third-quarter financial results and raised guidance. Pfizer reported quarterly earnings of $1.34 per share, which beat the estimate of $1.09 per share.

Why Pfizer Shares Are Rising Today

Pfizer (PFE) delivered earnings and revenue surprises of 24.07% and 7.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Beats Q3 Earnings and Revenue Estimates

Pfizer's (PFE) Q3 earnings and revenue smashed analysts' expectations, driven by sales of its vaccine against COVID-19.

Pfizer Q3 2021 Earnings Report Recap

Pfizer reported that earnings and sales more than doubled in the past quarter, and it raised its outlook for results the full year, thanks greatly to its Covid-19 vaccine.

Pfizer revenue and profits soar on its Covid vaccine business

US drugmaker expects to manufacture 3bn doses of vaccine with BioNTech this year

Pfizer raises Covid-19 vaccine sales forecast to $36bn for 2021

The European Union's health regulatory agency issued a positive opinion on Cibinqo as a potential eczema treatment.

A Pfizer Drug Moves Closer to Approval in Another Important Indication

Pfizer Inc (NYSE: PFE) reported Q3 adjusted EPS of $1.34, well ahead of the consensus of $1.09, and more than doubled from $0.59 posted a year ago.  The Company achieved Q3 revenues of $24.09 billion, more than doubled, reflecting operational growth of $13.4 billion and the favorable impact of foreign exchange of $421 million, surpassing the Wall Street estimate of $22.71 billion.

Pfizer More Than Doubles Earnings, Sales In Q3; Forecasts $36B From COVID-19 Vax Sales In FY21

Pfizer Inc on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in children.

Pfizer raises COVID-19 vaccine sales forecast to $36 billion for 2021

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2021 and raised 2021 guidance(4) for revenues and Adjusted diluted EPS(3) reflecting the net impact of its updated expectations for contributions to 2021 performance from both Comirnaty(1), the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine, as well as its business excluding Comirnaty(1). Additionally, Pfizer published this morning on its website the third-quarter 2021 earnings presentation and accom

PFIZER REPORTS THIRD-QUARTER 2021 RESULTS

Pfizer Inc. shares PFE, -0.23% jumped 2.5% in premarket trade Tuesday, after the company beat earnings estimates for the third quarter and raised guidance, boosted by strong sales of its COVID-19 vaccine, Comirnaty. The company posted net income of $8.146 billion, or $1.42 a share, for the quarter, up from $1.469 billion, or 26 cents a share, in the year-earlier period.

Pfizer shares jump 2.5% premarket as earnings beat, company raises guidance

Here's How Much Extra Money Pfizer Will Make From Vaccines for Younger Kids This Year

MercadoLibre

Trex

These stocks look like smart buys right now.

3 Smart Stocks to Hedge Against Inflation

BioNTech SE

The U.S. is preparing to roll out BioNTech SE BNTX and Pfizer Inc.'s PFE COVID-19 vaccine to children between the ages of 5 and 11-years-old later this week.

What to expect this week as the U.S. prepares to offer BioNTech and Pfizer's COVID-19 shots to young children

Pfizer's stock has corrected sharply in recent months.

Pfizer Is A Strong Medium-Term Buy

Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.

How Will Pfizer's (PFE) Key Drugs Impact Its Q3 Earnings?

Pfizer is scheduled to report its Q3 2021 results on Tuesday, November 2. We expect the company to likely post revenue and earnings well above the consensus estimates, primarily led by its Covid-19 vaccine.

Is Pfizer Stock Set To See Higher Levels Post Q3 Results?

Pfizer (PFE) reports Q3 earnings before market open on November 2. Can it continue to accelerate its earnings and revenue growth amid ongoing pandemic?

Pfizer Earnings: What to Look For

These are Insider's biggest healthcare stories for November 1.

The FDA has officially authorized Pfizer's COVID-19 vaccine for kids 5-11

In line with the expectations, the FDA has given emergency use authorization to Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine for children 5 through 11 years of age. Related Link:  FDA May Clear First COVID-19 Vaccine For Younger Kids, Probably Today: NYT.

FDA Paves Way for Pfizer/BioNTech's COVID-19 Shot In Young Children

Our preview of the upcoming week's earnings reports includes Pfizer (PFE), Square (SQ) and Moderna (MRNA).

Analysts Expect Pfizer (PFE) to Deliver a Blowout Q3

Community Health Systems

Merck

Teladoc

These 4 health care stocks are trending going into November 2021.

Best Stocks To Invest In 2021? 4 Health Care Stocks To Watch In November 2021

A small biotech, Oyster Point Pharma, will benefit the most from a recent FDA approval.

News for Pfizer Stock (PFE)